BYSI

BeyondSpring

Stock NASDAQ – Stock Market Prices, News & Analysis

BeyondSpring Inc est une société biopharmaceutique dédiée au développement de traitements innovants en oncologie et immuno-oncologie, focalisée sur la découverte et le développement de thérapies contre le cancer.

$ 1.73

2.98 %

United States Biotechnology KYG108301006

BeyondSpring

$ 1.73

2.98 %

BYSI

Oncologie Immuno-oncologie Recherche clinique Thérapies ciblées

United States Biotechnology KYG108301006

Price history of BeyondSpring

Performance & Momentum

6 Months 5.32 %

1 Year 34.13 %

3 Years 21.58 %

5 Years 83.27 %

Momentum

Unlock this indicator

Strategic Analysis

BeyondSpring • 2026

BeyondSpring Inc positions itself as a niche player in the U.S. biopharmaceutical sector, specializing in the research and development of innovative therapies in oncology and immuno-oncology. Its model is based on the clinical discovery of targeted cancer treatments, a highly technology-intensive field with disruptive potential.

Strengths

Deep expertise in immuno-oncology, a market segment expected to experience strong growth.
Clinical-stage drug pipeline that could transform the medium-term outlook.
Focus on targeted therapies that address unmet medical needs.

Weaknesses

Deteriorated long-term stock performance, reflecting operational or clinical challenges.
Lack of recent visible catalysts in the news flow that could drive a rebound in the stock.

Momentum

Current momentum remains weak and negative across most time horizons, indicating persistent bearish pressure despite a moderate momentum score. The absence of recent news limits short-term catalysts, which justifies heightened caution and a prudent stance while awaiting major clinical progress.

Ask our AI about BeyondSpring

Analysis performed 1 month ago